The impact of fungal infections on the course of disease in patients with COVID-19: a prospective observational study

Objective: to analyze the manifestations of fungal complications in COVID-19 and their impact on the course and outcome of the disease, taking into account comorbid pathology. Materials and methods: the types of fungal complications were studied in 118 adult hospitalized patients with COVID-19. The comparison groups consisted of 23 patients who died with fungal complications, 35 patients who died without fungal complications, 35 patients who recovered with fungal complications, and 25 patients who recovered without fungal complications. Results: it was established that the presence of fungal flora worsens the course of COVID-19 and is associated with an unfavorable prognosis. The timing of diagnosis and the location of the pathogen isolation are key: the detection of a fungal infection in the third week and later is significantly associated with a fatal outcome. Candidemia (the isolation of fungi from sputum) is an unfavorable prognostic sign, requiring instrumental monitoring and the prescription of antifungal therapy. Risk factors for developing fungal complications include age over 60, chronic cardiovascular and respiratory diseases, hypothyroidism, cancer, and HIV infection. Fungal pathogens are predominantly Candida albicans (96.6%). A combination of fungal and bacterial infections, particularly P. aeruginosa, MDR Acinetobacter, K. pneumoniae, and A. baumannii, is a prognostic marker for an adverse outcome. Conclusion: the data obtained support the need for early mycological monitoring in patients with COVID-19, especially those with risk factors, to promptly identify fungal complications and initiate appropriate therapy, which can significantly improve the prognosis.

1. Suleiman AS, Islam MA, Akter MS, Amin MR, Werkneh AA, Bhattacharya P. A meta-meta-analysis of co-infection, secondary infections, and antimicrobial resistance in COVID-19 patients. J Infect Public Health. 2023;16(10):1562-1590. https://doi.org/10.1016/j.jiph.2023.07.005

2. Sherman AC, Gray GE, Cao B, To KKW, Rouphael N, et al. Acute SARS-CoV-2 infection. Nat Rev Dis Primers. 2025;11(1):75. https://doi.org/10.1038/s41572-025-00662-x

3. Limami Y, Wahnou H, Ndayambaje M, Hba S, Chgari O, et al. SARS-CoV-2: A Liver Brief. WIREs Mech Dis. 2025;17(6):e70005. https://doi.org/10.1002/wsbm.70005

4. Kapur R, Okumura K, Ohira S, Isath A, Gandhi A, et al. Coronavirus Disease 2019 (COVID-19) in Heart Transplant Recipients and Anti-SARS-CoV-2 Monoclonal Antibodies: Experience, Lessons Learnt, and Future Challenges. Cardiol Rev. 2025;33(6):522-530. https://doi.org/10.1097/CRD.0000000000000640

5. Herta T, Berg T. COVID-19 and the liver - Lessons learned. Liver Int. 2021;41 Suppl 1(Suppl 1):1-8. https://doi.org/10.1111/liv.14854

6. Kamali Sarvestani H, Mahmoudi S, Afarinesh Khaki P, Ansari S, Ghaderkhani S, et al. Epidemiology, risk factors, species distribution, and antifungal susceptibility of candidemia among hospitalized patients with COVID-19. Curr Med Mycol. 2021;7(4):12-18. https://doi.org/10.18502/cmm.7.4.8406

7. Skóra M, Rosam K, Namysł M, Sepioło A, Gajda M, et al. Candida albicans Horizontal Transmission in COVID-19 Patients Hospitalized in Intensive Care Unit. J Fungi (Basel). 2024;10(12):864. https://doi.org/10.3390/jof10120864

8. Avdeeva M.G., Kulbuzheva M.I., Zotov S.V., Zhuravleva Ye.V., Yatsukova A.V. Microbial landscape in hospital patients with new coronavirus disease (COVID-19), antibiotic resistance comparison vs. Pre-covid stage: a prospective study. Kuban Scientific Medical Bulletin. 2021;28(5):14-28. (In Russ.) https://doi.org/10.25207/1608-6228-2021-28-5-14-28

9. Avdeeva M.G., Zotov S.V., Kulbuzheva M.I., Moshkova D.Y., Zhuravleva Y.V. Fungal complications with the new coronavirus infection COVID-19. Epidemiology and Infectious Diseases. 2021;26(6):252-269. https://doi.org/10.17816/EID108872

10. Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127-1140. https://doi.org/10.1038/s41564-022-01172-2

11. Mina S, Yaakoub H, Annweiler C, Dubée V, Papon N. COVID-19 and Fungal infections: a double debacle. Microbes Infect. 2022;24(8):105039. https://doi.org/10.1016/j.micinf.2022.105039

12. García-Salazar E, Benavidez-López S, Bonifaz A, Hernández-Mendoza EA, Ramírez-Magaña X, et al. Fungal coinfection/superinfection in COVID-19 patients in a tertiary hospital in Mexico. Biomedica. 2024;44(3):328-339. https://doi.org/10.7705/biomedica.7251

13. Altinkaya Çavuş M, Sav H. Opportunistic Candida Infections in Critical COVID-19 Patients. Pol J Microbiol. 2022;71(3):411-419. https://doi.org/10.33073/pjm-2022-036

14. Seyedjavadi SS, Bagheri P, Nasiri MJ, Razzaghi-Abyaneh M, Goudarzi M. Fungal Infection in Co-infected Patients With COVID-19: An Overview of Case Reports/Case Series and Systematic Review. Front Microbiol. 2022;13:888452. https://doi.org/10.3389/fmicb.2022.888452

15. Beştepe Dursun Z, Sipahioğlu H, Civan Yüksel R, Sav H, Çelik İ. Risk factors and lethality associated with Candidemia in severe COVID-19 patients. Curr Med Mycol. 2022;8(1):32-38. https://doi.org/10.18502/cmm.8.1.9212

16. Valencia-Ledezma OE, Reyes-Montes MDR, Acosta-Altamirano G, Frías-De-León MG, García-Salazar E, et al. Invasive Candidiasis Coinfection in Patients with Severe COVID-19 Disease: Scoping Review. Pathogens. 2025;14(5):466. https://doi.org/10.3390/pathogens14050466

17. Avdeeva M.G., Mozgaleva N.V., Parkhomenko Y.G. Malignant course of invasive pulmonary aspergillosis in the new coronavirus infection COVID-19. Epidemiology and Infectious Diseases. 2021;26(2):84-91. (In Russ.) https://doi.org/10.17816/EID105289

18. Savosin Yu.V., Shafranova S.K., Gaivoronskaya T.V., Avdeeva M.G., Vartanyan S.A. Rhinocerebral Form of Invasive Mycosis in COVID-19 Patients: Clinical Course, Diagnosis, Treatment Experience. Kuban Scientific Medical Bulletin. 2022;29(5):63-79. (In Russ.) https://doi.org/10.25207/1608-6228-2022-29-5-63-79

19. Colaneri M, Giusti EM, Genovese C, Galli L, Lombardi A, Gori A. Mortality of Patients With Candidemia and COVID-19: A Systematic Review With Meta-analysis. Open Forum Infect Dis. 2023;10(7):ofad358. https://doi.org/10.1093/ofid/ofad358

20. Özbek L, Topçu U, Manay M, Esen BH, Bektas SN, et al. COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases. Clin Microbiol Infect. 2023;29(6):722-731. https://doi.org/10.1016/j.cmi.2023.03.008

21. Liu A, Li Z, Su G, Li Y, Zhang Y, et al. Mycotic infection as a risk factor for COVID-19: A meta-analysis. Front Public Health. 2022;10:943234. https://doi.org/10.3389/fpubh.2022.943234

22. Caruso C, Marcon G, Accardi G, Aiello A, Calabrò A, et al. Role of Sex and Age in Fatal Outcomes of COVID-19: Women and Older Centenarians Are More Resilient. Int J Mol Sci. 2023;24(3):2638. https://doi.org/10.3390/ijms24032638

23. Pelle MC, Zaffina I, Provenzano M, Moirano G, Arturi F. COVID-19 and diabetes-Two giants colliding: From pathophysiology to management. Front Endocrinol (Lausanne). 2022;13:974540. https://doi.org/10.3389/fendo.2022.974540

24. Lamontagne SJ, Pizzagalli DA, Olmstead MC. Does inflammation link stress to poor COVID-19 outcome? Stress Health. 2021;37(3):401-414. https://doi.org/10.1002/smi.3017

25. Zobairy H, Salem MM, Ghajarzadeh M, Mirmosayyeb O, Mirsalehi M. Diabetes mellitus and other underlying conditions in patients with coronavirus disease 2019 associated rhino-orbito-cerebral mucormycosis: a systematic review and meta-analysis. J Laryngol Otol. 2022;136(9):788-798. https://doi.org/10.1017/S0022215122001074

26. Singulani JL, Silva DL, Lima CM, Magalhães VCR, Baltazar LM, et al. COVID-19 and candiduria: an investigation of the risk factors and immunological aspects. Braz J Microbiol. 2023;54(3):1783-1793. https://doi.org/10.1007/s42770-023-01042-x

27. Li J, Ghosh TS, McCann R, Mallon P, Hill C, et al. Robust cross-cohort gut microbiome associations with COVID-19 severity. Gut Microbes. 2023;15(1):2242615. https://doi.org/10.1080/19490976.2023.2242615